期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 22, 期 33, 页码 7440-7452出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v22.i33.7440
关键词
Immune checkpoint; Therapeutic anticancer target; Inflammation; Randomized clinical trial; Pancreatic adenocarcinoma
资金
- JSPS [268605371]
- AstraZeneca
- Eli Lilly and Company
- Bayer AG
Pancreatic adenocarcinoma (PAC) is one of the most deadly malignant neoplasms, and the efficacy of conventional cytotoxic chemotherapy is far from satisfactory. Recent research studies have revealed that immunosuppression and inflammation are associated with oncogenesis, as well as tumor development, invasion, and metastasis in PAC. Thus, immunosuppression-related signaling, especially that involving immune checkpoint and inflammation, has emerged as novel treatment targets for PAC. However, PAC is an immune-resistant tumor, and it is still unclear whether immune checkpoint or anti-inflammation therapies would be an ideal strategy. In this article, we will review immune checkpoint and inflammation as potential targets, as well as clinical trials and the prospects for immunotherapy in PAC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据